5th ESPT CONGRESS
PRECISION MEDICINE AND PERSONALISED HEALTH
SEVILLE, SPAIN

2019
October
16-18

European Society for Pharmacogenomics and Personalised Therapy

In collaboration with the Spanish Society of Pharmacogenetics and Pharmacogenomics (SEFF)

www.2019esptcongress.eu
UNDER THE AUSPICES OF:

EFLM
EUROPEAN FEDERATION OF CLINICAL CHEMISTRY
AND LABORATORY MEDICINE

IFCC
International Federation of Clinical Chemistry
and Laboratory Medicine

SIF
SOCIETÀ ITALIANA DI FARMACOLOGIA
Dear participant,

we are very pleased to welcome you here at the 5th International Congress of the European Society for Pharmacogenomics and Personalised Therapy (ESPT 2019) in Seville, Spain. A meeting bringing together leading international scientists and healthcare professionals who are actively working in the fields of Pharmacogenomics and Personalised Therapy. After successful events in the previous years (Catania 2017, Budapest 2015, Lisbon 2013, Bled 2011), we are very happy to have our 2019 meeting here in Spain, on this occasion in collaboration with the Spanish Society for Pharmacogenetics and Pharmacogenomics (SEFF). As ESPT, we are very grateful for this hospitality!

The theme of the ESPT 2019 congress is Precision Medicine and Personalised Health, and the program we have put together is, to our hoping, interesting and challenging for you. It is addressing the latest developments in the field of pharmacogenetics/pharmacogenomics, including liquid biopsy/cell free DNA as an fast upcoming approach to guide drug therapy. We are proud to include in our congress keynote speakers such as Prof. Dr. Sir Munir Pirmohamed, Prof. Dr. Ingolf Cascorbi, Dr. Lili Milani, Prof. Dr. Wolfgang Sadee, Prof. Dr. Daniel Mueller, Prof. Dr. Mike Caulfield, Prof. Dr. Klaus Pantel and many other excellent speakers. In addition, we have 100 posters with the latest results of ongoing research from mostly ambitious young scientists! Please take the opportunity to interact and discuss these latest findings with the poster presenters during the breaks. On Friday, the poster committee will hand out the award for the best poster contribution.

A special word of welcome and thanks to our sponsors, who have enabled us to have this meeting here. I am confident that you as a participant will enjoy the opportunity to interact with them, to obtain the latest information on technical as well as software developments.

As ESPT and SEFF Board, we hope that you will enjoy your stay in Seville. Enjoy your congress!

Kindest regards,

Prof. Dr. Miquel Taron – President SEFF
Dr. Cristina Rodríguez-Antona – Secretary SEFF
Prof. Dr. Adrián Llerena – Vicepresident SEFF, Board ESPT
Prof. Dr. Ron van Schaik – President ESPT
ORGANIZING COMMITTEE

Miquel Taron
(University of Seville, President SEFF)

Cristina Rodriguez-Antona
(CNIO, Madrid)

Adrián Llerena
(University of Extremadura, Badajoz)

Ron van Schaik
(Erasmus MC Rotterdam, President ESPT)

ESPT BOARD

Ron H.N. van Schaik
(President)

Vangelis G. Manolopoulos
(President Elect)

Maurizio Simmaco
(Treasurer)

Sanja Stanković
(General Secretary)

Marc Ansari
(Board Member)

Peter Jacobs
(Board Member)

Adrian Llerena
(Board Member)

Janja Marc
(Board Member)

Ingolf Cascorbi
(Board Member)

Csilla Sipeky
(Board Member)

Sophie Visvikis-Siest
(Board Member)
SPEAKERS

Alonso Sanchez Angel, Biomedical Research Center of Navarre, Pamplona, Spain
Ansari Marc, University of Geneva, Switzerland
Brunet Mercè, Hospital Clínic of Barcelona, Spain
Carracedo Alvarez Angel Maria, University of Santiago de Compostela, Spain
Cascorbi Ingolf, University of Kiel, Germany
Caulfield Mark, William Harvey Heart Centre, University of London, UK
Daly Ann K., Newcastle University, UK
Danesi Romano, University of Pisa, Italy
de la Haba Juan, Hospital Reina Sofia, Cordoba, Spain
del Re Marzia, University Hospital of Pisa, Italy
Dopazo Joaquin, Clinical Bioinformatics Area, FPS, Hospital Virgen del Rocio, Seville, Spain
Gurwitz David, Tel Aviv University, Israel
Henricks Linda M., Leiden University Medical Centre, The Netherlands
Hachad Houda, Translational Software, Bellevue, WA, United States
Huezo-Diaz Patricia, University of Geneva, Switzerland
Ingelman-Sundberg Magnus, Karolinska Institutet, Stockholm, Sweden
Kasper Dagmar, Agena Bioscience, Hamburg, Germany
Lamy Pierre-Jean, Imagenome, Montpellier, France
Lianidou Evi, University of Athens, Greece
Llerena Adrián, University of Extremadura, Badajoz, Spain
Llerena Nuria, Bellvitge Biomedical Research Institute of Barcelona, Spain
Manolopoulos Vangelis, University of Thrace, Alexandropoulis, Greece
Milani Lili, University of Tartu, Estonia
Mueller Daniel, Centre for Addiction and Mental Health of Toronto, Canada
Niemi Mikko, University of Helsinki, Finland
Nofziger Charity, PharmGenetix Gmbh, Salzburg, Austria
Oellerich Michael, University of Göttingen, Germany
Oram Richard, Institute of Biomedical & Clinical Science, University of Exeter Medical School, UK
Pantel Klaus, University Medical Center Hamburg-Eppendorf, Germany
Patrinos George, University of Patras, Greece
Paulmichl Markus, Humanomed Center Althofen, Austria
Pearson Ewan, University of Dundee, Scotland, UK
Pirmohamed Munir, University of Liverpool, UK
Rodríguez-Antona Cristina, National Centre for Oncological Research, Madrid Spain
Sabater Ana, Eugenomic, Barcelona, Spain
Sadee Wolfgang, The Ohio State University, Columbus, USA
Schwab Matthias, Institute of Clinical Pharmacology Stuttgart, Germany
Serrano Marí Jose, University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain
Shaman Jeff, Coriell Life Sciences, Philadelphia, USA
Simmaco Maurizio, University La Sapienza, Rome, Italy
Sipeky Csilla, University of Turku, Finland
Suarez-Kurtz Guilherme, Brazilian National Cancer Institute, Brazil
Taron Miquel, Synlab, Madrid, Spain
van Schaik Ron, Erasmus MC, Rotterdam, The Netherlands
Vanoni Simone, Anif/Niederalm, Austria
SCIENTIFIC PROGRAMME

WEDNESDAY 16th October

08:30 Registration
09:30 Opening: Ron van Schaik (ESPT President) - Miquel Taron (SEFF President)

SESSION 1 - PHARMACOGENETICS OVERVIEW
Chairs: Ron van Schaik, Miquel Taron
09:45 Key note lecture - Pharmacogenetics of cutaneous adverse drug reactions - Sir Munir Pirmohamed
10:15 Key note lecture - Pharmacogenetics of drug induced liver injury - Ann Daly
10:45 Key note lecture - An initiative for early drug discovery with a pharmacogenomic perspective from Galicia - Angel Carracedo

11:15 Coffee Break

SESSION 2 - PSYCHIATRY
Chairs: Adrian Llerena, David Gurwitz
11:45 Towards the implementation of pharmacogenomics in psychiatry - Daniel Mueller
12:10 Genomic biomarkers for the efficacy of oxytocin in autism spectrum disorder - David Gurwitz
12:35 New Pharmacogenetics software gNomic and drug interactions - Ana Sabater

13:00 Lunch Break and Poster Visits

SESSION 3 - CYP2D6 GENOTYPING
Chairs: Magnus Ingelman-Sundberg, Urs Meyer
14:30 Unraveling CYP2D6 genotyping: the optimal strategy - Charity Nofziger
14:55 Functional characterization of known and unknown CYP2D6 variants using a cell-based in vitro system - Simone Vanoni

15:35 INDUSTRY SPONSORED SESSION AGENA BioSciences
Aspects of Molecular Analysis with Liquid Biopsy - Dagmar Kasper
Liquid biopsy to personalize lung cancer treatment: overcoming the challenges - Pierre-Jean Lamy

16:15 Coffee Break

SESSION 4 - ONCOLOGY
Chairs: Cristina Rodriguez-Antona, Csilla Sipeky
16:45 Personalizing taxane treatment: from genetic variants to concomitant medication - Cristina Rodriguez-Antona
17:10 Update on DPYD testing for safer fluoropyrimidine therapy - Linda Henricks
17:35     PGx and tamoxifen breast cancer: an update - Matthias Schwab
18:00     What is the Foundation Medicine contribution in Precision Medicine? - Juan de la Haba
18:30     OPENING RECEPTION

THURSDAY 17th October

SESSION 5 - LIQUID BIOPSY & CANCER
Chair: Romano Danesi, Janja Marc
08:30     Key note lecture - Liquid biopsy: a new diagnostic concept in oncology - Klaus Pantel
09:05     EGFR and lung cancer - Romano Danesi
09:30     Circulating predictive biomarker of response to immunotherapy - Marzia del Re
09:55     Molecular characterization of Circulating Tumor Cells: an update on technologies and clinical potential - Evi Lianidou
10:20     Coffee Break

SESSION 6 - LIQUID BIOPSY & TRANSPLANTATION
Chair: Mercè Brunet, Maurizio Simmaco
10:50     Graft-derived cell-free DNA as a marker for detection of rejection and graft injury after solid organ transplantation - Michael Oellerich
11:15     Pharmacogenetics for guiding solid organ transplantation therapy: the BAROTAC study - Nuria Lloberas
11:40     Using Therapeutic Drug Monitoring in optimizing tacrolimus-personalized therapy and patient care in solid organ transplantation: the IATDMCT Consensus Report - Mercè Brunet
12:05     INDUSTRY SPONSORED SESSION Thermo Fisher
Outcomes from large population PGx testing - Jeff Shaman
12:50     Lunch Break and Poster Visits

SESSION 7 - BIOBANK INITIATIVES, REGULATORY ASPECTS
Chair: Vangelis Manolopoulos, Luis Lopez
14:00     The UK 100,000 Genomes Project: transforming health initiative - Sir Mark Caulfield
14:30     Personalised Medicine based on common and rare genetic variants in Estonia - Lili Milani
14:55     Regulatory aspects regarding implementation of PGx: SmPC information and EMA considerations - Markus Paulmichl
15:20     Personalised medicine of prostate cancer: impact of genomic biomarkers - Csilla Sipeky
SESSION 8 - PGx GENES
Chairs: Ingolf Cascorbi, Anna Gonzalez-Neira
16:15 CYP3A genotyping - worth to consider it clinically? - Ingolf Cascorbi
16:40 The role of rare genetic variants for interindividual differences in drug metabolism, toxicity and response - Magnus Ingelman-Sundberg
17:05 Interindividual variability of CYP2D6, CYP3A4 and CYP7A1: underlying causes and clinical implications - Wolfgang Sadee
17:30 Implementing clinical pharmacogenetic programs: perspectives from a service provider Houda Hachad

18:00 ESPT GENERAL ASSEMBLY until 19:30
19:00 SEFF GENERAL ASSEMBLY
20:00 SEFF 1ST Pharmacogenetic Profficiency Testing Accreditations
21:00 CONGRESS DINNER

FRIDAY 18th October

SESSION 9 - PGx AND PERSONALIZED MEDICINE CLINICAL IMPLEMENTATION INITIATIVES IN SPAIN
Chairs: Maria Jesus Arranz, Salvador Aliño
09:00 MedeA: A global Implementation initiative of Personalized Medicine in a Public Health Care Service based on e-health - Adrián Llerena
09:25 Bioinformatics and the Andalusian initiative for personalized medicine - Joaquin Dopazo
09:50 Innovative purchase in Andalusia for liquid biopsy - Maria Jose Serrano
10:15 NAGEN: Proyecto Genoma 1000 Navarra - Angel Alonso Sánchez
10:40 Coffee Break

SESSION 10 - ESPT RESEARCH GROUPS
Chairs: Marc Ansari, Sofia Siest
11:10 PGx and drug transporters - Mikko Niemi
11:35 What is the impact of pharmacogenomic to predict Sinusoidal obstructive syndrome in pediatric Stem cell transplantation - Marc Ansari, Patricia Huezo-Diaz
12:00 PGx in diabetes care - Ewan Pearson
12:25 Pharmacogenetics and personalised medicine in anticoagulation: latest developments - Vangelis Manolopoulos
12:45  Lunch Break and POSTER AWARDS

**SESSION 11 - FUTURE PERSPECTIVES**  
*Chairs: Sanja Stankovic, Francisco Abad*

14:00  Prediction and classification of type 1 diabetes using genetic risk scores - *Richard Oram*

14:25  Implementation of Pharmacogenomics in Europe: The U-PGx project - *George Patrinos*

14:50  Pharmacogenomic Implications of Population Admixture in Latin America  
*Guilherme Suarez-Kurtz*

15:15  The microbiome and response to drugs - *Maurizio Simmaco*

15:40  Discussion and final remarks - *Miquel Taron, Ron van Schaik*

16:00  END - Farewell Drinks

---

**CLOSED MEETINGS**

**WEDNESDAY 16th OCTOBER**

13:30  ESPT Board Meeting  
Alanda Room - until 15:30

**THURSDAY 17th OCTOBER**

11:00  ESPT National Societies Meeting  
Alanda Room - until 12:00

**FRIDAY 18th OCTOBER**

09:00  ESPT Corporate Members Meeting  
Alanda Room - until 10:00
Scalable Pharmacogenetic Testing

With the MassARRAY® System from Agena Bioscience

Whether you’re just getting started or growing an existing testing program, Agena Bioscience has the PGx solutions to make you successful. Get up and running quickly with the content you need. Process from one to thousands of samples a day without excessive reagent waste or cost. Easily update content to meet changing needs.

Maximize Efficiency, Minimize Cost

- **COMPREHENSIVE DETECTION**
  Genotyping & CNV detection on the same run.

- **ROBUST PERFORMANCE**
  Accurate results, no need for duplicate samples.

- **COST EFFECTIVE**
  Affordable upfront costs without excessive failures or waste.

For Research Use Only. Not for use in diagnostic procedures. 
agenabio.com

MassARRAY is a registered trademark of Agena Bioscience, Inc. GEN0022 01
001
COMPREHENSIVE ANALYSIS IDENTIFIES UGT1A3 VARIANTS AS MAJOR DETERMINANTS OF TELMISARTAN PHARMACOKINETICS
Hirvensalo Päivi, Tornio Aleksi, Neuvonen Mikko, Tapaninen Tuija, Paile-Hyvärinen Maria, Backman Janne, Niemi Mikko

002
EFFECT OF GENE-DRUG INTERACTIONS LINKED TO CLOPIDOGREL AND CILOSTAZOL ON PLATELET REACTIVITY AMONG PATIENTS WITH PERIPHERAL ARTERY DISEASE
Duconge Jorge, Hernandez-Suarez Dagmar F., Nunez Hector, Melin Kyle

003
MACHINE LEARNING ALGORITHM FOR PREDICTING WARFARIN DOSES IN CARIBBEAN HISPANICS USING PHARMACOGENETIC DATA
Roche-Lima Abiel, Feliu-Maldonado Roberto, Roman-Santiago Adalis, Rodriguez-Maldonado Jovaniel, Nieves Brenda, Carrasquillo Kelvin, Duconge Jorge

004
NOVEL MICRORNAS ASSOCIATED WITH ADVANCED HUMAN ATHEROSCLEROTIC LESIONS - POTENTIAL BIOMARKERS AND THERAPEUTIC TARGETS
Manea Simona-Adriana, Vlad Mihaela-Loredana, Lazar Alexandra-Gela, Cosac Monica-Teodora, Muresian Horia, Simionescu Maya, Manea Adrian

005
THE ROLE OF PHARMACOGENETICS IN PRECISION MEDICINE: REINTRODUCTION OF ANTICOAGULANT THERAPY FOLLOWING INTRACRANIAL HEMORRHAGE
Šimičević Livija, Vrlic Kirhmajer Majda, Cohen Herak Desiree, Ganoci Lana, Bozina Tamara, Bozina Nada

006
FREQUENCIES OF PHARMACOGENETIC VARIANTS AND PREVALENCE OF PHARMACOGENETICALLY RELEVANT MEDICATIONS IN FINNISH UNIVERSITY HOSPITAL PATIENTS
Litonius Kaisa, Kristiansson Kati, Tarkiainen Katriina, Ukkola-Vuoti Liisa, Orpana Arto, Lindstedt Mats, Nyrönen Tommi, Perola Markus, Niemi Mikko

007
PILOT STUDY TO EVALUATE THE CLINICAL IMPLEMENTATION OF PHARMACOGENETIC ANALYSIS IN ORGAN TRANSPLANTATION
Herrero Marí José, Sendra Luis, Olivera Gladys, Cervera José Vicente, Montoro Juan, Piñana José Luis, Sanz Jaime, Montalvá Eva, López-Andújar Rafael, Sales Gabriel, Almenar Luis, Hernandez Julio, Aliño Salvador Francisco
008
THE DUTCH EVIDENCE-BASED PHARMACOGENETIC GUIDELINES: CURRENT STATUS AND IMPLEMENTATION

009
THE EFFICIENCY OF PPI USE IN TURKISH PATIENTS: CYP2C19 PHARMACOGENETIC TESTING
Susleyici Belgin, Cevik Mehtap, Karaalp Atila, Yurdakul Selen, Canbolat Ismail Polat, Gunduz Hakan, Ceyhan Berrin, Yazici Gonca, Cagatay Penbe, Ciftci Cavlan

010
THE INTERRELATIONSHIP BETWEEN KLOTHO GENE POLYMORPHISM G-395A AND LEFT VENTRICULAR HYPERTROPHY IN HEMODIALYSIS PATIENTS
Cvetkovic Tatjana, Apostolovic Branislav, Stefanovic Nikola, Pavlovic Dusica, Cvetkovic Mina, Petkovic Igor, Pavlovic Dimitrije, Mitic Branka

011
INVESTIGATION OF THE EFFECT OF HUMAN GENETIC VARIATIONS ON THE OUTCOME(TDM) OF VORICONAZOLE TREATMENT IN PEDIATRIC CANCER PATIENTS

CYP2D6 GENOTYPING EXPERT ANALYSES

012
CYP2D6 GENOTYPE-PHENOTYPE ANALYSIS BASED ON POPULATION PHARMACOKINETIC MODELLING OF VORTIOXETINE
Frederiksen Trine, Areberg Johan, Ellen Schmidt, Bjerregaard Stage Tore, Brøsen Kim

013
CYTOCHROME P450 2D6 *3, *4, *6 AND *41 ALLELE SPECIFIC COPY NUMBER DETERMINATION IN CYP2D6XN SAMPLES USING DDP Congo de Jonge Evert, Matic Maja, van Schaik Ron

014
THE ROLE OF RISKY POLYMORPHIC VARIANTS OF CYP2D6 GENE IN THE EFFICACY OF VALPROIC ACID THERAPY IN PATIENTS WITH EPILEPSY
Zobova Svetlana, Dmitrenko Diana, Shnayder Natalia, Prusova Tatjana, Yakovleva Kristina, Pravdin Denis, Yakimova Yana
DECISION SUPPORT TOOLS

015
DO CYP3A4*20 AND CYP3A4*22 ALLELES AFFECT THE PHARMACOKINETIC PARAMETERS OF CYP3A4 SUBSTRATES?
Saiz-Rodríguez Miriam, Ochoa Dolores, Belmonte Carmen, Román Manuel, Zubiaur Pablo, Santos María, Rodríguez-Antona Cristina, Abad-Santos Francisco

016
IMPLEMENTATION OF CLINICAL DECISION SUPPORT SYSTEM FOR DOSING IN PSYCHOPHARMACOTHERAPY IN PATIENTS WITH AFFECTIVE DISORDERS BASED ON THE PHARMACOGENOMIC MARKERS
Mikhail Zastrozhin, Valentin Skryabin, Evgeny Bryun, Alexander Sorokin, Dmitry Sychev

017
LEVERAGING GLOBAL TECH TO PUT IOT TO WORK FOR CARE TEAMS
Lunzenfichter Gilles

018
IBERIAN DATABASE BUILDING OF PHARMACOGENETIC INDICATORS, ACCORDING TO THE INFORMATION PRESENT IN THE SUMMARY OF DRUG CHARACTERISTICS AVAILABLE IN PORTUGAL AND SPAIN
Advinha Ana Margarida, Cachão Rita de Oliveira, Alípio Carolina, Correia Catarina, Martins-Vaz Rita, André Francisco, Gonçalves Rui, De Andrés Fernando, Llerena-Ruiz Adrián, Lopes Manuel José

DIABETES

019
EVALUATION OF NOVEL ADIPOKINES (OMENTIN-1, APELIN AND CHEMERIN) AS POTENTIAL BIOMARKERS OF PRESENCE AND SEVERITY OF DIABETIC RETINOPATHY IN TYPE 2 DIABETES MELLITUS PATIENTS
Yasir Md, Senthilkumar Gp

020
EVALUATION OF THE SUITABILITY OF NINETEEN PHARMACOGENOMICS BIOMARKERS FOR INDIVIDUALIZED METFORMIN THERAPY FOR TYPE 2 DIABETES PATIENTS
Xhakaza L, Masilela C, Pearce B, October Z, Johnson R, Adeniyi OV, Ongole JJ, Benjeddou Mongi

021
FREQUENCY OF CYP2C9 (*2, *3 AND IVS8-109A>T) ALLELIC VARIANTS AND THEIR CLINICAL IMPLICATIONS AMONG MEXICAN PATIENTS WITH DIABETES MELLITUS TYPE 2 UNDERGOING TREATMENT WITH GLIBENCLAMIDE AND METFORMIN
Cuautle Rodríguez Patricia, Rodríguez Rivera Nidia, De Andrés Fernando, Castillo Nájera Fernando, Llerena Adrián, Molina Guarneros Juan Arcadio
METFORMIN PHARMACOKINETICS IN JORDANIANS: EFFECTS OF ORGANIC CATIONS TRANSPORTERS
Hakooz Nancy, Jarrar Yazun Bashir, Zihlif Malik, Imraish Amer, Arafat Arafat, Hamed Saja

STUDY OF THE GENETIC POLYMORPHISM OF THE SLC22A1, SLC22A2 AND SLC22A3 GENES AMONG ECUADORIAN DIABETES MELLITUS TYPE 2 PATIENTS
Terán Enrique, Dorado Pedro, De Andrés Fernando, Bonilla Mauro, Tana Leandro, Mora Lorena, Estévez María, Llerena Adrián

TAILORING TYPE II DIABETES TREATMENT: 5-HTTLPR AND VNTR STIN2 POLYMORPHISM AND METFORMIN EFFICACY
Ochi Taichi, Denig Petra, Heerspink Hiddo, Hak Eelko, Wilffert Bob

DRUG TRANSPORTERS

EFFECTS OF ABCB1 GENETICS VARIANT ON TACROLIMUS PHARMACOKINETICS IN ALGERIAN ADULT KIDNEY TRANSPLANT PATIENTS
Boughrara Wefa, Boudia Fatma, Aberkane Meriem, Moghtit Fatima Zohra, Toumi Houari

FDA APPROVED CLINICALLY USED DRUGS AS BREAST CANCER RESISTANCE PROTEIN INHIBITORS
Deng Feng, Kidron Heidi, Niemi Mikko

GENOTYPING PLATFORMS

COPY NUMBER VARIATION ASSOCIATED WITH ANTI-TNF RESPONSE AND THE APPEARANCE OF PARADOXICAL PSORIASIFORM REACTIONS IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
Ovejero-Benito María Carmen, Sanz-García Ancor, Hevia Laura, Reolid Alejandra, Muñoz-Aceituno Ester, Llamas-Velasco Mar, Navarro Raquel, Abad-Santos Francisco, Daudén Esteban

EFFECTS OF CES1 GENE POLYMORPHISM ON ANTIPLATELET EFFECT OF RECEPTOR P2Y12 BLOCKER CLOPIDOGREL
Osipova Darya, Mirzaev Karin, Sychev Dmitry
029
IDENTIFICATION OF BIOMARKERS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ERLOTINIB AND AFATINIB
Svedberg Anna, Vikingsson Svante, Vikström Anders, Hornstra Niels, Kentson Magnus, Brandén Eva, Koyi Hirsh, Bergman Bengt, Green Henrik

030
WHOLE-EXOME SEQUENCING ASSOCIATES’ GENETIC VARIATION IN HEMATOPOIESIS PATHWAYS WITH GEMCITABINE/CARBOPLATIN-INDUCED THROMBOCYTOPENIA
Björn Niclas, Sigurgeirsson Benjamín, Svedberg Anna, Pradhananga Sailendra, Brandén Eva, Koyi Hirsh, Lewensohn Rolf, De Petris Luigi, Apellániz-Ruiz Maria, Rodríguez-Antona Cristina, Lundeberg Joakim, Grén Henrik

031
GENOTYPING OF THE DPYD GENE. INITIATIVE TURNED INTO REALITY
Comes Raga Ana, Guzmán Luján Carola, Guallart Noguera Cristina, Ferriz Vivancos Jorge, Ávila Andrade Claudio, Camps Herrero Carlos, Guaita Martínez Marcos, Marcaida Benito Goitzane, Ferrer Bolufer Irene

032
A RARE DPYD VARIANT (C.257C>T) ALTERS ENZYME ACTIVITY AND IS ASSOCIATED WITH SEVERE CAPECITABINE TOXICITY

033
ADVANCED RENAL CANCER PATIENTS WITH TUMOR MUTATIONS IN PBRM1 AND KDM5C SHOW IMPROVED RESPONSE TO ANTI-ANGIOGENIC THERAPY
Santos María, Lanillos Javier, Roldán-Romero Juan María, Calsina Bruna, Pulgarín Marta, Martínez Ángel, Letón Rocio, Montero-Conde Cristina, Cascón Alberto, Robledo Mercedes, Beuselinck Benoit, Rodríguez-Antona Cristina, García-Donas Jesús

034
ASSOCIATION OF RISKY POLYMORPHIC VARIANTS OF OPRM1 GENE WITH THE EFFECTIVENESS OF PAIN THERAPY IN PATIENTS WITH PANCREATIC MALIGNANT NEOPLASMS
Bobrova Olga, Dmitrenko Diana, Zobova Svetlana, Yakimova Yana, Shnayder Natalia

035
BENEFITS OF NEXT GENERATION SEQUENCING IN THE SCREENING OF DPD DEFICIENCY
Larrue Romain, Hennart Benjamin, Broly Franck
036
GERMLINE BIOMARKERS GUIDING DOCETAXEL TREATMENT OF PROSTATE CANCER
Varnai Reka, Koskinen Leena M, Mäntylä Laura E, Szabo Istvan, FitzGerald Liesel M, Sipeky Csilla

037
HLA-G & CADHERIN PROFILE EXPRESSION, AND ITS PROGNOSTIC VALUE IN RENAL CELL CARCINOMA.
Concha Mayayo Julia, Garcia Garcia Cristina Belen, Sánchez Zalabardo Jose Manuel, López de Val Alejandro, Ribate Molina Maria Pilar, Gomez Barrera Manuel, Saez Gutierrez Berta

038
OUTCOME DEFINITION INFLUENCES THE RELATIONSHIP BETWEEN GENETIC POLYMORPHISMS OF ERCC1, ERCC2, SLC22A2 AND CISPLATIN NEPHROTOXICITY IN ADULT TESTICULAR CANCER PATIENTS
Zazuli Zulfan, Otten Leila S., Drögemöller Britt I., Medeiros Mara, Wright Galen E.B., Vijverberg Susanne J.H., Masereeuw Rosalinde, Roos Colin J.D., Liu Geoffrey, Carleton Bruce C., Maitland-van der Zee Anke H.

039
PTEN EXPRESSION AND MUTATIONS IN TSC1, TSC2 AND MTOR ARE ASSOCIATED WITH RESPONSE TO RAPALOGS IN PATIENTS WITH RENAL CELL CARCINOMA.

040
THE SINGLE NUCLEOTIDE POLYMORPHISM RS7121 IN THE GENE GNAS AS A BIOMARKER FOR TUMOR PROGRESSION AND POOR SURVIVAL IN CANCER PATIENTS
Möhlendick Birte, Ting Saskia, Schmid Kurt Werner, Siffert Winfried

041
WHAT TO GENOTYPE TO PREDICT FLUOROPYRIMIDINES TOXICITY - POSSIBLE ROLE OF DPYD 496A>G VARIANT
Ganoci Lana, Simicevic Livija, Bilic Ivan, Bozina Tamara, Bozina Nada

042
THE ASSOCIATION OF SINGLE-NUCLEOTIDE POLYMORPHISMS WITH EFFICACY AND TOXICITY OF CABAZITAXEL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
de With Mirjam, Belderbos Bodine PS, Singh Rajbir K, Agema Bram C, El Bouazzaoui Samira, Oomen-de Hoop Esther, de Wit Ronald, van Schaik Ron HN, Mathijssen Ron HJ, Bins Sander

043
BIOMARKERS AND TUMOR AGGRESSIVENESS
Topolcan Ondrej, Kucera Radek, Karlkova Marie, Svobodova Sarka, Simanek Vaclav, Dolejsova Olga, Hora Milan, Finek Jindrich, Treska Vladislav
044 BIOBANKS USE IN ONCOLOGY RESEARCH
Topolcan Ondrej, Karlikova Marie, Kucera Radek, Kinkorova Judita, Simanek Vaclav, Racek Jaroslav, Svobodova Sarka

045 EFFECTS OF PHARMACOGENETIC VARIANTS ON VEMURAFENIB-RELATED TOXICITIES IN PATIENTS WITH MELANOMA
de With Mirjam, Goey Andrew KL, Mathijssen Ron HJ, Singh Rajbir K, Agema Bram C, Oomen-de Hoop Esther, van der Veldt Astrid AM, van Schaik Ron HN, Bins Sander

046 ASSOCIATION BETWEEN ABCB1 GENETIC VARIANTS AND PERSISTENT CHEMOTHERAPY-INDUCED ALOPECIA IN BREAST CANCER PATIENTS TREATED WITH DOCETAXEL
Nunez-Torres Rocio, Rodrigo-Faus Maria, Tejera-Perez Hugo, Pita Guillermo, del Monte-Millan Maria, Herraez Belen, Bermejo Begoña, Lluch Anna, Martin Miguel, Gonzalez-Neira Anna

047 PAIN

048 ASSOCIATION OF RISKY POLYMORPHIC VARIANTS OF OPRM1 GENE WITH THE EFFECTIVENESS OF PAIN THERAPY IN PATIENTS WITH PANCREATIC MALIGNANT NEOPLASMS
Bobrova Olga, Dmitrenko Diana, Zobova Svetlana, Shnayerd Natalia, Yakimova Yana, Prusova Tatiana

049 GENETIC CASE-CONTROL ASSOCIATION STUDY OF METAMIZOLE-INDUCED AGRANULOCYTOSIS
Cismaru Anca Liliana, Rudin Deborah, Ibañez Luisa, Liakoni Evangelina, Kreutz Rheinhold, Carvajal Alfonso, Lucena M. Isabel, Martin Javier, Sancho Ponce Esther, Ericsson Niclas, Molokhia Mariam, collaborators E U D A C, Largiadèr Carlo, Haschke Manuel, Hallberg Pär, Wade

050 IDENTIFICATION OF GENETIC DETERMINANTS FOR CENTRAL PAIN SENSITIZATION IN FIBROMYALGIA PATIENTS
Gloor Yvonne, Mouterde Médéric, Matthey Alain, Poloni Estella S., Chabert Jocelyne, Simona Aurélien, Bovet Luc, Besson Marie, Piguet Valérie, Cedraschi Christine, Pickering Gisèle, Kosek Eva, Ehret Georg, Desmeules Jules

051 PHARMACOGENETICS APPLIED TO TAPENTADOL EFFECTIVENESS ON AMBULATORY CHRONIC PAIN PATIENTS
Barrachina Bernabey Jordi, Muriel Serrano Javier, Margarit Ferri Cesar, Ballester Pura, López-Gil Santiago, López-Gil Vicente, del Barco Guillermo, Flor Andrea, Morales Domingo, Peiró Ana Maria
051 TRAMADOL FROM CYP2D6 PHARMACOGENETIC TESTING TO CLINICAL DATA
Cevik Mehtap, Karaalp Atila, Gunduz Hakan, Yazici Gonca, Cagatay Penbe, Susleyici Belgin

052 ULTRA-RAPID CYP2D6-METABOLIC PHENOTYPE INFLUENCE ON CHRONIC NON-CANCER PAIN PATIENTS WITH PRESCRIPTION OPIOID USE DISORDER
Muriel Javier, del Barco Guillermo, Barrachina Jordi, Margarit César, Planelles Beatriz, Inda María del Mar, Morales Domingo, Peiró Ana María

053 PATIENT PERSPECTIVES

054 PREDICTION OF TOXICITY A METHOTREXATE BY MEANS OF GENETIC TESTS IN PATIENTS DIAGNOSED MODERATE-SEVERE PSORIASIS
Membrive Cristina, Pérez Ramírez Cristina, Maldonado Montoro María del Mar, Jiménez Puerta Gonzalo, Arias Santiago Salvador, Jiménez Morales Alberto

055 PEDIATRIC HEMATO-ONCOLOGY

056 MIRNA-PHARMACOGENOMICS FOR THE PREDICTION OF OUTCOME IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
Gutierrez-Camino Angela, Artetxe Aizpea, Santos-Zorrozua Borja, Martin-Guerrero Idoia, Garcia de Andoin Nagore, Sastre Ana, Astigarraga Itziar, Lopez-Lopez Elixabet, Garcia-Orad Africa

057 PHARMACOGENETICS OF CHEMOTHERAPY RESPONSE IN OSTEOSARCOMA: A GENETIC VARIANT IN SLC7A8 IS ASSOCIATED WITH PROGRESSIVE DISEASE
Hurkmans Evelien, Vos Hanneke, Groothuismink Johanne, van der Graaf Winette, Flucke Uta, Schreuder Bart, Hagleitner Melanie, Gelderblom Hans, van der Straaten Tahar, Bovée Judith, Cleton-Janssen Anne-Marie, de Bont Eveline, Bras Johannes, Caron Huib, Windsor Rachael, Wh

059 PREDICTIVE POLYMORPHISMS OF THE EFFICACY OF THE INDUCTION CHEMOTHERAPY TREATMENT IN NEUROBLASTOMA
Olivera Gladys, Yáñez Yania, Herrero María José, Berlanga Pablo, Gargallo Pablo, Sendra Luis, Hervás David, Font de Mora Jaime, Segura Vanesa, Ramal Desiré, Fernández-Delgado Rafael, Castel Victoria, Cañete Adela, Aliño Salvador Francisco
PGX AND EMA/FDA REGULATORY ASPECTS

057
GENE SIGNATURES OF EARLY RESPONSE TO ANTI-TNF DRUGS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
Salvador Martín Sara, Raposo Irene, Navas Víctor Manuel, Rodriguez Alejandro, Gonzalez Rafael, Sánchez Cesar, Tolín Mar, Pujol-Muncunill Gemma, Bossacoma Ferrán, Moreno Ana, Magallares Lorena, Fobelo María José, Millán Antonio, Eizaguirre Javier, Blanca José Antonio, Benguria Alberto, Vazquez Enrique, Dopazo Ana, Abarca Judith, García-González Xandra, Sanjurio María, Lopez-Fernández Luis A.

058
PHARMACOGENOMIC PROFILING OF HUMAN DRUG TARGETS – TOWARDS TRANSLATING GENETIC VARIATION INTO PERSONALIZED PRESCRIBING
Zhou Yitian, Lauschke Volker Martin

059
ROLE OF TLR2 DNA VARIANTS AS MARKERS OF RESPONSE TO ANTI-TNF TREATMENT IN INFLAMMATORY BOWEL DISEASE
Abarca Zabalía Judith, Salvador-Martín Sara, Pujol-Muncunill Gemma, Bossacoma Ferrán, Navas Víctor, Viada Francisco, J. Muñoz Rosana, Moreno Ana, Magallares Lorena, Clemente Susana, Segarra Oscar, Rodríguez Alejandro, Loverdos Ines, Merino-Bohorquez Vicente, Cuadrado Ca

060
PHARMACOGENOMICS OF STATIN-RELATED MYOPATHY (SRM): A CASE REPORT
Esquivel Bernard, Juginovic Alen, Mikula Ivan, Primorac Dragan, Donaldson Morgan

061
PHARMACOGENOMIC GUIDED THERAPY IN PATIENT WITH MAJOR DEPRESSIVE DISORDER
Juginovic Alen, OneOme, Mikula Ivan, Primorac Dragan, Donaldson Morgan, Esquivel Bernard

PSYCHIATRY

062
A ONE-YEAR LONGITUDINAL FOLLOW-UP STUDY OF TREATMENT COMPLIANT SUICIDE SURVIVORS: TRACKING THE RELATION BETWEEN COMBINED CYP2D6-CYP2C9 METABOLIC CAPACITY WITH PHARMACOTHERAPY AND SUICIDE REATTEMPTS
Peñas-Lledó Eva M., Guillaume Sebastien, De Andrés Fernando, Fariñas Humberto, Kahn Jean P., Leboyer Marion, Llerena Adrián, Courtet Philippe

063
ASSOCIATION BETWEEN DRUG-GENE-INTERACTION, DRUG-DRUG-INTERACTION, AND DRUG-DRUG-GENE-INTERACTION AND EARLY DISCONTINUATION, SWITCHING AND DOSE ADJUSTMENT OF (ES) CITALOPRAM: AN EXPLORATIVE STUDY.
ASSOCIATION OF ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SYNDROME WITH POLYMORPHISM RS1800955 OF DRD4 GENE PROMOTER

Vaiman Elena, Moskaleva Polina, Shnayder Natalia, Nasyrova Regina

ASSOCIATION OF AUTISM SPECTRUM DISORDER WITH THE DIFFERENT GENETIC BIOMARKERS IN THE BANGLADESHI CHILDREN


CYP2D6 GENOTYPE, GENETIC ANCESTRY AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE EFFECTS IN CUBAN PATIENTS WITH SCHIZOPHRENIA

Roblejo Balbuena Hilda, Marcheco Teruel Beatriz, González Pal Salvador, Monzón Benítez Giselle, Marin Padrón Lilia C, De Andrés Fernando, Llerena Adrián

CYP2D6 POLYPORPHISM, POLYPHARMACY AND SEVERE ANTIDEPRESSANT DRUG REACTIONS

Peñas-Lledó Eva M., Martín Reyes Migdyrai, De Andrés Fernando, Llerena Adrián

DEVELOPING OF NON-INVASIVE PROTOCOL TO DETERMINE NON-STRESSED AND STRESSED STATE USING “METABOLOMIC FOOTPRINT” BY DIRECT INFUSION MASS SPECTROMETRY.

Lorenzo-Tejedor Mónica, Goñi Guillermina, De la Cámara Concepción, Bailón Raquel, Aguiló Jordi, Maria Luisa Bernal

EFFECTS OF CYP3A4 GENETIC POLYMORPHISM ON THE EFFICACY AND SAFETY OF DIAZEPAM IN PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME

Skriabin Valentin, Zastrozhin Mikhail, Bryun Evgeny, Sychev Dmitry

GENETIC POLYMORPHISMS OF KDR ARE NOT ASSOCIATED WITH MAJOR DEPRESSION

Nunes Fernanda, Ferezin Letícia, Pereira Sherianne, Menezes Itiiana, Baes Cristiane, Juruena Mário, Lacchini Riccardo

INTERPLAY OF CYP2D6, ABCB1 AND ABCG2 POLYMORPHISMS – EFFECT ON EXPOSURE, EFFICACY AND SAFETY OF LONG-ACTING RISPERIDONE IN SCHIZOPHRENIA PATIENTS

Ganoci Lana, Živković Maja, Trkulja Vladimir, Božina Tamara, Šagud Marina, Lovrić Mila, Božina Nada
072
PHARMACOGENETICS AND THERAPEUTIC DRUG MONITORING APPLICATION IN A CLOZAPINE PATIENT.
Sangüesa Sangüesa Estela, Concha Mayayo Julia, Cirujeda Christine, Padilla Pedro Pablo, Ribate Molina Maria Pilar, Garcia Garcia Cristina Belen

073
PHARMACOGENETICS OF BENZODIAZEPINE TRANQUILIZER PHENAZEPAM: COMBINATORIAL ANALYSIS OF CYP450 AND P-GLYCOPROTEIN GENETIC POLYMORPHISMS
Tereshchenko Olesya, Ivashchenko Dmitriy, Temirbulatov Ilyas, Grishina Elena, Sychev Dmitry

074
WHAT IS BETTER: CONDUCTING PHARMACOGENETIC STUDIES BEFORE OR AFTER THE DEVELOPMENT OF ADVERSE DRUG REACTIONS?
Moskaleva Polina, Vaiman Elena, Bochanova Elena, Shnayder Natalia, Nasyrova Regina

SOLID ORGAN TRANSPLANTATION

075
GENETIC VARIABILITY OF ENZYMES AND TRANSPORTERS WITH KEY-ROLE IN PHARMACOKINETICS OF CYCLOSPORINE AND TACROLIMUS-ANALYSIS OF DATA PUBLISHED FOR TRANSPLANTED PATIENTS FROM SERBIA
Beletic Andjelo, Tijanic Aleksandra, Stankovic Sanja

076
PROCALCITONIN’S ROLE FOR PNEUMONIA DIAGNOSIS IN LUNG TRANSPLANT PATIENTS READMITTED TO INTENSIVE CARE UNIT
Tejada Sofia, Mazo Cristopher, Romero Anabel, Peña Yolanda, Pont Teresa, Rello Jordi

077
THE INFLUENCE OF TACROLIMUS INTRAINDIVIDUAL VARIABILITY AND CYP3A5 GENE POLYMORPHISM ON KIDNEY FUNCTION IN LATE PERIOD AFTER KIDNEY TRANSPLANTATION
Stefanovic Nikola, Cvetkovic Tatjana, Velickovic-Radovanovic Radmila, Mitic Branka, Damnjanovic Ivana, Catic-Djordjevic Aleksandra, Pavlovic Dusica

078
THE USE OF PHARMACOGENETICCS AS A TOOL TO IMPROVE THE INDIVIDUAL IMMUNOSUPPRESSIVE PHARMACOTHERAPY AND KNOWLEDGE OF AN ASSOCIATION OF TRANSPLANTED HEPATIC PATIENTS.
Concha Mayayo Julia, Sangüesa Sangüesa Estela, Saez Gutierrez Berta, Garcia Garcia Cristina Belen, Ribate Molina Maria Pilar
OTHER

079
ASSESSMENT OF THE PHENOTYPIC IMPACT OF DPYD POLYMORPHISMS C.85C>T, C.496A>G, AND 1601G>A IN HEALTHY BLOOD DONORS.
Hamzic Seid, Schärer Dominic, Ramette Alban, Fontana Stefano, Amstutz Ursula, Largiadèr Carlo

080
ASSOCIATION BETWEEN CTLA4, CD80 AND CD86 GENE POLYMORPHISMS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT
Márquez Pete Noelia, Pérez Ramírez Cristina, Maldonado Montoro María del Mar, Cáliz Cáliz Rafael, Jiménez Morales Alberto

081
ASSOCIATION BETWEEN HLA-DQA1-HLA-DRB1 VARIANT RS2647087 AND THIOPURINE INDUCED PANCREATITIS.
Nielen Suzanne, Broekman Mark, van Marrewijk Corine, Guchelaar Henk-Jan, de Jong Dirk, Coenen Marieke

082
ASSOCIATION OF THE PTGS1 POLYMORPHISM AND THE OCCURRENCE OF UPPER GASTROINTESTINAL BLEEDING (UGIB).
Forgerini Marcela, de Nadai Tales Rubens, Urbano Gustavo, Herdeiro Maria Teresa, Figueiras Adolfo Guzman, Cachafeiro Maruxa Zapata, Mastroianni Patrícia de Carvalho

083
DEPENDENCE OF MICROBIOTA ANALYSIS ON THE 16S RRNA TARGET REGION
Borro Marina, Gentile Giovanna, Simmaco Maurizio

084
EFFECT OF CYP3A5*3 POLYMORPHISM ON ANTI-INFLAMMATORY THERAPY IN CHILDREN WITH BRONCHIAL ASTHMA
Zastrozhina Anastasiya, Sychev Dmitry

085
EFFECT OF POLYMORPHISMS IN VKORC1 AND CYP2C9 VARIANTS ON ACENOCOUMAROL MAINTENANCE DOSE, STROKE RECURRENCE AND BLEEDING EVENTS USING A GENOME-WIDE ASSOCIATION STUDY
086  
ENHANCING PRECISION MEDICINE THROUGH CLINICAL MASS SPECTROMETRY PLATFORM  
Svinarov Dobrin

087  
GENOMIC ANCESTRY, CYP2D6, CYP2C9 AND CYP2C19 AMONG LATIN-AMERICANS  

088  
HCP5 RS2395029: A RAPID AND INEXPENSIVE ALTERNATIVE TO HLA-B*57:01 GENOTYPING TO PREDICT THE ABACAVIR HYPERSENSITIVITY REACTION (ABC-HSR) IN IBERIANS.  
Zubiaur Pablo, Saiz-Rodriguez Miriam, Villapalos Gonzalo, Navares-Gómez Marcos, Abad-Santos Francisco

089  
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF CYP4V2 GENETIC VARIANTS EXHIBITING DECREASED ACTIVITY OF LAURIC ACID METABOLISM  
Lee Su-Jun, Jarrar Yazun, Shin Jae-Gook

090  
PERCEPTION OF PHARMACY STUDENTS TOWARD PHARMACOGENOMIC KNOWLEDGE AND ATTITUDE AMONG DIFFERENT UNIVERSITIES IN JORDAN AND WEST BANK OF PALESTINE  
Jarrar Yazun, Rami Musleh, Mohamad Hawash, Jarrar Qais

091  
PHARMACOGENETIC CHARACTERISATION OF THE EMPAR COHORT  
Stingl Julia, Haenisch Britta, Linder Roland, Langner Daria, Garling Marco, Roethlein Christoph, Gomm Willy, Heß Steffen, Steffens Michael, Hübner Tatjana, Fracowiak Jochen

092  
PHARMACOGENETICALLY RELEVANT VARIANTS IN THE AZORES ISLANDS (PORTUGAL)  
Pereirinha Tânia, Bulhões Sara, Brilhante Maria José, Mota-Vieira Luísa, Castelo Branco Claudia

093  
PHARMACOGENETICS OF DRUG–GENE INTERACTION AND DRUG–DRUG–GENE INTERACTION IN ELDERLY PEOPLE: A PILOT STUDY ON CYP2C9 AND CYP2C19  
Verde Zoraida, García-Aldea Sara, Rodríguez-Díez Jose Andrés, Velasco Verónica, Fernández-Araque Ana
094
POLYMORPHISMS OF PIK3CA ARE NOT ASSOCIATED WITH THE RISK FOR ERECTILE DYSFUNCTION

095
RELATIONSHIP BETWEEN CYP1A2, CYP2C9, CYP2C19, CYP2D6 AND CYP3A4 METABOLIC PHENOTYPE AND GENOTYPE IN THE NICARAGUAN MESTIZO POPULATION
De Andrés Fernando, Altamirano Tinoco Catalina, Ramírez-Roa Ronald, Montes Mondragón Carlos, Arias Zepeda Ariel, Dorado Pedro, Castellano Cisnero Efrén, Peñas-Lledó Eva M., Llerena Adrián

096
TRANSCRIPTOMIC ANALYSIS OF CHRONIC IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH ELTROMBOPOAG.
Hernández-Sánchez Jesús María, Bastida José María, Alonso-López Diego, Benito Rocío, González-Porras José Ramón, De las Rivas Javier, Hernández Rivas Jesús María, Rodríguez-Vicente Ana Eugeni

097
PHENYTOIN ADVERSE REACTION IN A CHILD WITH DEFECTIVE CYP2C9. A CASE REPORT IN PEDIATRIC INTENSIVE CARE UNIT
Cocciadiferro Dario, Agolini Emanuele, Marano Marco, Nicoletti Ferdinando, Pro Stefano, Goffredo Bianca Maria, Novelli Antonio

098
GLOBAL OUTLOOK ON PHARMACOGENOMICS EDUCATION

099
INSIGHTS INTO THE BIOLOGICAL ROLE OF THIOPURINE S-METHYLTRANSFERASE
Smid Alenka, Urbancic Dunja, Kotar Anita, Plavec Janez, Mlinaric-Rascan Irena

100
GENOME-WIDE STUDY IDENTIFIES ASSOCIATION BETWEEN HLA-B*55:01 AND PENICILLIN ALLERGY USING ELECTRONIC HEALTH RECORDS OF BIOBANK PARTICIPANTS
Krebs Kristi, Lepamets Maarja, Bovijn Jonas, Censis Jenny, Lindgren Cecilia, Holmes Michael, Mägi Reedik, Milani Lili, Fadista João
The world’s largest collection of SNP genotyping assays

Prepare to launch into your next discovery

We have expanded our menu of Applied Biosystems™ TaqMan® SNP Genotyping Assays, and we now offer **over 17 million predesigned assays** for your convenience. With this expansion, the SNP you want is now more likely to be available.

Gain the confidence you deserve with this updated collection of TaqMan Assays, the gold-standard technology in genotyping and genetic variation analysis.

- A rigorous pipeline with over 90 parameters to design the optimal primer and probe combinations with the specificity you need
- Functional quality testing on at least 20 samples of gDNA for each assay
- Flexible formats to accommodate any number of targets and samples

- Proven technology, backed by over 40,000 publications and over 300 patents
- Guaranteed performance*—if a TaqMan Assay does not perform according to specifications, we’ll replace it at no cost or credit your account

Check out the updated web experience with the TaqMan Assays search page.

Web ordering just got easier with our new search tool, expanded assay content, and publication references. Additional collections such as DME assays and a custom TaqMan Assay Design Tool are also available.

* To see the full guarantee, go to [thermofisher.com/taqmanguarantee](https://thermofisher.com/taqmanguarantee).

Find your assay at [thermofisher.com/taqman](https://thermofisher.com/taqman)

For Research Use Only. Not for use in diagnostic procedures. © 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. TaqMan is a registered trademark of Roche Molecular Systems, Inc., used under permission and license. COL17018 0818
GENERAL INFO

CONGRESS VENUE

NH HOTEL COLLECTION SEVILLA
Avda. Diego Martínez Barrio, 8 - 41013 Sevilla SPAIN
https://www.nh-hotels.com/hotel/nh-collection-sevilla

POSTER EVALUATION

During the Conference posters will be displayed, divided by topic. The Poster Evaluation Committee will vote the best one and the Winner will be announced on Thursday 17th at the end of the scientific sessions. The winning poster will be posted on www.2019ESPTcongress.eu

WI-FI CONNECTION

Wi-Fi connection will be available in the whole building; no password needed.

OFFICIAL LANGUAGE

All lectures will be in English.

CONGRESS DINNER
(not included in the registration fee)

The Congress Dinner will be held on Thursday, October 17th at restaurant ABEDES TRIANA
Address: Calle Betis 69, Seville (it is about 3 Km away from the congress venue, not walking distance)

- Reduced fee € 50,00 per person
- Accompanying persons and exhibitors € 60,00 per person
PLATINUM SPONSORS

Agena Bioscience
Thermo Fisher Scientific

GOLD SPONSORS

illumina
Roche

SILVER SPONSORS

biologis
BIO-RAD
Eugenomic
Novogene
Pharmagenetix
Randox
Translational software
Yourgene Health

BRONZE SPONSORS

DrugPIN
MCD Automated Molecular Diagnostics

OTHER SPONSOR

Cansearch

fondation de recherche contre le cancer de l’enfant
ESPT EXECUTIVE OFFICE

Marina Festinese
Via Carlo Farini 81
20159 Milano (Italy)
Tel. +39 0266802323-959
office@esptsociety.eu
www.esptsociety.eu

ORGANISING SECRETARIAT

MZ Congressi srl - Via C. Farini, 81
20159 Milano (Italy)
Tel. +39 02 66802323
Fax +39 02 6686699
info@2019ESPTcongress.eu
www.mzcongressi.com